ImmuCell Co. (NASDAQ:ICCC) Sees Large Decrease in Short Interest

ImmuCell Co. (NASDAQ:ICCC) was the target of a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 13,200 shares, a drop of 22.8% from the February 28th total of 17,100 shares. Based on an average trading volume of 8,000 shares, the short-interest ratio is presently 1.7 days. Currently, 0.2% of the company’s shares are sold short.

ImmuCell Trading Up 6.6 %

ICCC stock traded up $0.33 during midday trading on Wednesday, reaching $5.33. The stock had a trading volume of 23,318 shares, compared to its average volume of 19,320. The company has a quick ratio of 1.44, a current ratio of 3.11 and a debt-to-equity ratio of 0.36. ImmuCell has a twelve month low of $3.34 and a twelve month high of $5.82. The firm has a market cap of $47.50 million, a price-to-earnings ratio of -10.66 and a beta of 0.62. The business has a fifty day simple moving average of $5.10 and a two-hundred day simple moving average of $4.48.

ImmuCell (NASDAQ:ICCC) last posted its quarterly earnings results on Tuesday, February 25th. The biotechnology company reported $0.06 earnings per share for the quarter. ImmuCell had a negative net margin of 15.99% and a negative return on equity of 15.32%. The business had revenue of $7.75 million during the quarter.

Institutional Trading of ImmuCell

Several institutional investors and hedge funds have recently made changes to their positions in ICCC. Citadel Advisors LLC bought a new stake in ImmuCell in the fourth quarter valued at about $149,000. Northern Trust Corp increased its stake in shares of ImmuCell by 51.0% in the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock valued at $229,000 after acquiring an additional 14,982 shares during the last quarter. Dauntless Investment Group LLC acquired a new stake in shares of ImmuCell in the 4th quarter valued at approximately $676,000. Geode Capital Management LLC boosted its stake in ImmuCell by 13.9% during the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock worth $332,000 after acquiring an additional 7,878 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. grew its holdings in ImmuCell by 100.0% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock valued at $125,000 after purchasing an additional 12,178 shares during the period. Institutional investors own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.